DNA分析可能有助于預(yù)測哪個腫瘤可能對化學(xué)療法產(chǎn)生抵抗而哪個腫瘤不會。Andy Minn及其同事發(fā)現(xiàn)了一組稱為干擾素相關(guān)DNA損傷抵抗特征（IRDS）的遺傳標(biāo)記,，它們與一個動物模型中對放射性療法和/或化學(xué)療法產(chǎn)生抵抗有關(guān),。這組科學(xué)家在34個癌細(xì)胞系和乳腺癌患者身上證實(shí)了他們的發(fā)現(xiàn)。
大多數(shù)關(guān)于遺傳標(biāo)記的研究提供了哪些患者有殘留病以及需要進(jìn)一步治療的信息,。相比之下,，IRDS基因特征提供了關(guān)于殘留病是否將對治療做出響應(yīng)的信息。對于乳腺癌患者,，IRDS狀態(tài)預(yù)測了手術(shù)后輔助化療的效果,。這組作者說,，由于IRDS基因能讓癌癥對化療和放療產(chǎn)生抵抗，而且讓IRDS基因沉默可能導(dǎo)致對一種常見化療藥物阿霉素的重新敏感,，把IRDS作為研究重點(diǎn)有可能提供有用的信息,，從而發(fā)現(xiàn)逆轉(zhuǎn)擁有IRDS表達(dá)疾病的患者的治療抵抗的方法。他們提出IRDS狀態(tài)有可能讓臨床醫(yī)生提供對額外的癌癥治療的風(fēng)險和收益的個人化評估,。（生物谷Bioon.com）
生物谷推薦原始出處：
PNAS November 10, 2008, doi: 10.1073/pnas.0809242105
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer
Ralph R. Weichselbaum, Hemant Ishwaran, Taewon Yoon, Dimitry S.A. Nuyten, Samuel W. Baker, Nikolai Khodarev, Andy W. Su, Arif Y. Shaikh, Paul Roach, Bas Kreike, Bernard Roizman, Jonas Bergh, Yudi Pawitan, Marc J. van de Vijver, and Andy J. Minn
Individualization of cancer management requires prognostic markers and therapy-predictive markers. Prognostic markers assess risk of disease progression independent of therapy, whereas therapy-predictive markers identify patients whose disease is sensitive or resistant to treatment. We show that an experimentally derived IFN-related DNA damage resistance signature (IRDS) is associated with resistance to chemotherapy and/or radiation across different cancer cell lines. The IRDS genes STAT1, ISG15, and IFIT1 all mediate experimental resistance. Clinical analyses reveal that IRDS(+) and IRDS(?) states exist among common human cancers. In breast cancer, a seven–gene-pair classifier predicts for efficacy of adjuvant chemotherapy and for local-regional control after radiation. By providing information on treatment sensitivity or resistance, the IRDS improves outcome prediction when combined with standard markers, risk groups, or other genomic classifiers.
